Saakshi Khattri, MD, discusses how real-world comparative effectiveness data suggest a potential class-level signal for risankizumab and IL-23 inhibition in reducing the risk of psoriatic arthritis among patients with psoriasis.

Saakshi Khattri, MD, describes how risk factors for psoriatic arthritis influence her decision to use IL-23 inhibitors such as risankizumab as first-line systemic therapy in psoriasis.

Saakshi Khattri, MD, reviews 5-year extension data of risankizumab in psoriatic arthritis, emphasizing sustained radiographic non-progression and durability of clinical response.

Saakshi Khattri, MD, summarizes integrated long-term safety data across risankizumab’s psoriasis and psoriatic arthritis programs.

Saakshi Khattri, MD, explains how multi-year safety data with risankizumab inform discussions with patients who are concerned about the long-term risks of remaining on therapy.

Saakshi Khattri, MD, discusses the comparable safety profile of risankizumab in psoriasis and psoriatic arthritis and the minimal need for routine laboratory monitoring.

Saakshi Khattri, MD, outlines her key practice-changing takeaways for dermatologists and rheumatologists.